secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2025-07-01T23:59:59+00:00
Accession:  0001193125-25-153393
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology enters co-promotion agreement with Kyowa Kirin for ziftomenib in AML
--------------------------------------------------------------------------------

- Co-promotion and medical affairs agreement with Kyowa Kirin US for ziftomenib, a menin inhibitor for AML, dated June 27, 2025.
- Kyowa Kirin US will co-promote for up to a certain percentage of US details; parties share costs equally.
- Kura leads US medical affairs; parties jointly develop health economics and outcomes research strategy.
- Term continues until mutual cessation of US commercialization or expiration of Collaboration Agreement term (up to 10 years after first commercial sale).
- Agreement automatically terminates with Collaboration Agreement; either party can terminate for uncured material breach.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000119312525153393/0001193125-25-153393-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000119312525153393/d911089d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-153393

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer